Clicky

Nuvectis Pharma, Inc.(NVCT)

Description: Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.


Keywords: Cancer Biopharmaceutical Life Sciences Biology Treatment Of Cancer Tyrosine Kinase Oncogenes Cancer Research Kinase Small Molecule Proto Oncogene Tyrosine Protein Kinase Src

Home Page: www.nuvectis.com

NVCT Technical Analysis

1 Bridge Plaza
Fort Lee, NJ 07024
United States
Phone: 201 614 3150


Officers

Name Title
Mr. Ron Bentsur M.B.A. Co-Founder, Chairman, CEO & Pres
Dr. Enrique Poradosu Ph.D. Co-Founder, Exec. VP, Chief Scientific & Bus. Officer
Mr. Shay Shemesh Co-Founder, EVP, Chief Devel. & Operations Officer
Mr. Michael Carson CPA VP of Fin.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 5.3973
Price-to-Sales TTM: 0
IPO Date: 2022-02-04
Fiscal Year End: December
Full Time Employees: 8
Back to stocks